Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans

Hypertension

Volumn 33, Issue 3, 1999, Pages 879-886

  Azizi, Michel ^c   Ezan, Eric ^a   Reny, Jean Luc ^d   Wdzieczak Bakala, Joanna ^b   Gerineau, Vincent ^b   Ménard, Joël ^d  

^a Institut National de la Recherche Agronomique   (France)

^b CNRS   (France)

^c HÔPITAL BROUSSAIS   (France)

^d NONE

Author keywords

Angiotensin converting enzyme inhibitor kidney failure; Metabolism; Oligopeptides; Peptidyl dipeptidase A

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SERASPENIDE;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG DETERMINATION; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; HUMAN; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC CLEARANCE RATE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0032993365     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.33.3.879     Document Type: Article

References (23)

1. Erdös EG. Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension. 1990;16:363-370.
2. Wei L, Alhenc-Gelas F, Corvol P, Clauser E. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem. 1991;266:9002-9008.
3. Lenfant M, Wdzieczak-Bakala J, Guittet E, Prome JC, Sotty D, Frindel E. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc Natl Acad Sci U S A. 1989;86: 779-782.
4. Guigon M, Bonnet D. Inhibitory peptides in hematopoiesis. Exp Hematol. 1995;23:477-481.
5. Rieger K-J, Saez-Servent N, Papet M-P, Wdzieczak-Bakala J, Morgat J-L, Thierry J, Voelter W, Lenfant M. Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl seryl aspartyl lysyl proline. Biochem J. 1993; 296:1-6.
6. Rousseau A, Michaud A, Chauvet M-T, Lenfant M, Corvol P. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem. 1995;270:3656-3661.
7. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet J-M, Lenfant M, Corvol P, Ménard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest. 1996;97:839-844.
8. Azizi M, Ezan E, Nicolet L, Grognet J-M, Ménard J. High plasma level of acetyl-seryl-aspartyl-Iysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension. 1997;30:1015-1019.
9. Comte L, Lorgeot V, Volkov L, Allegraud A, Aldigier JC, Praloran V. Effects of the angiotensin-converting enzyme inhibitor enalapril on blood haematopoietic progenitors and acetyl-N-Ser-Asp-Lys-Pro concentrations. Eur J Clin Invest. 1997;27:788-790.
10. Rousseau-Plasse A, Wdzieczak-Bakala J, Lenfant M, Ezan E, Genet R, Robinson S, Briscoe T, Melville J, Riches A. Lisinopril, an angiotensin I-converting enzyme inhibitor, prevents in vivo the entry into cell cycle of murine hematopoietic stem cells following irradiation. Exp Hematol. 1998;26:1-6.
11. Nussberger J, Brunner DB, Waeber B, Brunner HR. In vitro renin inhibition to prevent generation of angiotensins during determination of angiotensin I and II. Life Sci. 1988;42:1683-1688.
12. Pradelles P, Probert Y, Créminon C, Liozon E, Massé A, Frindel E. Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay. Biochem Biophys Res Commun. 1990;170:986-993.
13. Ezan E, Carde P, Le Kerneau J, Ardouin T, Thomas F, Isnard F, Deschamps de Paillette E, Grognet JM. Pharmacokinetics in healthy volunteers and patients of NAc-SDKP (Seraspenide), a negative regulator of hematopoiesis. Drug Metab Dispos. 1994;22:843-848.
14. Cushman DW, Cheung MS. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol. 1971;20:1637-1648.
15. Nussberger J, Brunner D, Keller I, Brunner HR. Measurement of converting enzyme activity by antibody-trapping of generated angiotensin II: comparison with two other methods. Am J Hypertens. 1992;5:393-398.
16. Chauveau D, Guyenne TT, Cumin F, Chatellier G, Corvol P, Ménard J. Investigation of the biochemical effects of renin inhibition in normal volunteers treated by an ACE inhibitor. Br J Clin Pharmacol. 1992;33: 253-260.
17. Simon D, Romestand B, Huang H, Badouaille G, Fehrentz J-A, Pau B, Marchand J, Corvol P. Direct simplified, and sensitive assay of angiotensin II in plasma extracts performed with a high-affinity monoclonal antibody. Clin Chem. 1992;38:1963-1967.
18. Kosus JB, Raia JJ, DeFelice EA, Barone JA, Deeter RG. Comparative clinical pharmacology of ACE inhibitors. In: Kostis JB, DeFelice EA, eds. Angiotensin Converting Enzyme Inhibitors. New York, NY: Alan R Liss, Inc; 1987:19-54.
19. Hoyer J, Schulte KL, Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin Pharmacokinet. 1993;24:230-254.
20. Carde P, Chastang C, Goncalves E, Mathieu-Tubiana N, Vuillemin E, Delwail V, Corbion O, Vekhoff A, Isnard F, Ferrero J-M, Garcia-Giralt E, Gimonet J-F, Stoppa A-M, Léger-Picherit E, Fadel E, Monpezat J-P, Munck J-N, Domenge C, Khayat D, Guilhot F. Séraspénide (acétyl SDKP): étude en phase I-II d'un inhibiteur de l'hématopoièse la protégeant de la toxicité de monochimiothérapies aracytine et ifosfamide. C R Acad Sci Paris. 1992;315:545-550.
21. Fyhrquist F, Forslund T, Tikkanen I, Gronhagen-Riska C. Induction of angiotensin converting enzyme in rat lung with captopril (SQ 14225). Eur J Pharmacol. 1980;67:473-475.
22. Jackson B, Johnston CI. Angiotensin converting enzyme during acute and chronic enalapril therapy in essential hypertension. Clin Exp Pharmacol Physiol. 1984;11:355-360.
23. Wei L, Clauser E, Alhenc-Gelas F, Corvol P. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem. 1992;267: 13398-13405.